Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.

GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.

GV contributed to a round for MIT-founded small molecule cancer drug spinout Kronos Bio, adding to $18m raised by the latter 14 months ago.

BTG's International Asia unit contributed $11m to $16.8m series B round, taking a 10% stake in the medical isotopes developer.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Woodford Investment Management will auction unlisted biotech investments which include Oxford Nanopore in a process that could take three months to reach its conclusion.

Investors such as Persol and Sompo have provided series B capital for ExaWizards, a developer of AI technology that caters to the elder care service industry.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University of Chicago immuno-oncology spinout Pyxis Oncology has been backed by corporate investment vehicle Leaps by Bayer in its first funding round.

Florida State University cornea repair drug developer Trefoil Therapeutics added funding from investors including subsidiaries of Aju Corporation and Access Biotechnology to bring its total to $33.2m.